Risperidone Oral Suspension is indicated for the following:
Risperidone is indicated for the treatment of schizophrenia.
Risperidone is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorders.
Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others.
Risperidone is indicated for the short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation diagnosed according to DSM-IV criteria, in whom the severity of aggressive or other disruptive behaviours require pharmacologic treatment. Pharmacological treatment should be an integral part of a more comprehensive treatment programme, including psychosocial and educational intervention. It is recommended that risperidone be prescribed by a specialist in child neurology and child and adolescent psychiatry or physicians well familiar with the treatment of conduct disorder of children and adolescents.
Summary of Product Characteristics
Read this summary of product characteristics for further information about Risperidone Rosemont Oral Solution. Click below to navigate to the EMC.
Patient Information Leaflet
Read this patient information leaflet about Risperidone Rosemont Oral Solution, what it’s used for and possible side effects. Click below to navigate to the EMC.
Risperidone Oral Solution
|Click here for Audio Version
|Do not freeze
|Shelf Life (Closed Bottle/Open Bottle)
|36 months / 3 months
For further product information and pricing please use the form below and a member of the team will be in touch
Stay updated via our App
A new Rosemont Pharmaceuticals App for Healthcare Professionals is launching soon.